drugset
Drugs / PEP503
last change May 2023 re-read 3 minutes ago

PEP503

Other / unclassified

Developed for
head and neck squamous cell carcinoma · rectal cancer
Investigated by
PharmaEngine

Trials 2

today NCT02901483 · Ph 1/2 NCT02465593 · Ph 1/2
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT02901483 Oct 2016 → Aug 2020 head and neck squamous cell carcinoma PharmaEngine Terminated Met primary
Phase 1/2 NCT02465593 Jun 2015 → Jul 2021 rectal cancer PharmaEngine Terminated Met primary

Press releases naming this drug 1 release

DateIssuerRelease
2021-01-05 PharmaEngine PharmaEngine, Inc. Announces First Results for PEP503(NBTXR3) in Rectal Cancer Study at ASCO-GI 2021 pharmaengine.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as PEP503 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02465593 ↗
1

NCT02901483 ↗
Modality Other / unclassified “PEP503 (NBTXR3) nanoparticles” PMID 37166053 ↗ May 2023